Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/34758
Title: Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
Author: Jones, Paul W.
Rennard, Stephen I.
Agustí García-Navarro, Àlvar
Channez, Pascal
Magnusen, Helgo
Fabbri, Leonardo
Donohue, James F.
Bateman, Eric D.
Gross, Nicholas J.
Lamarca, Rosa
Caracta, Cynthia
Garcia Gil,Esther
Keywords: Malalties pulmonars obstructives cròniques
Chronic obstructive pulmonary diseases
Issue Date: 26-Apr-2011
Publisher: BioMed Central
Abstract: Background: The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Methods: In two double-blind, 52-week studies, ACCLAIM/COPD I (n = 843) and II (n = 804), patients were randomised to inhaled aclidinium 200 μg or placebo once-daily. Patients were required to have a postbronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity ratio of ≤70% and FEV1 <80% of the predicted value. The primary endpoint was trough FEV1 at 12 and 28 weeks. Secondary endpoints were health status measured by St George"s Respiratory Questionnaire (SGRQ) and time to first moderate or severe COPD exacerbation. Results: At 12 and 28 weeks, aclidinium improved trough FEV1 versus placebo in ACCLAIM/COPD I (by 61 and 67 mL; both p < 0.001) and ACCLAIM/COPD II (by 63 and 59 mL; both p < 0.001). More patients had a SGRQ improvement ≥4 units at 52 weeks with aclidinium versus placebo in ACCLAIM/COPD I (48.1% versus 39.5%; p = 0.025) and ACCLAIM/COPD II (39.0% versus 32.8%; p = 0.074). The time to first exacerbation was significantly delayed by aclidinium in ACCLAIM/COPD II (hazard ratio [HR] 0.7; 95% confidence interval [CI] 0.55 to 0.92; p = 0.01), but not ACCLAIM/COPD I (HR 1.0; 95% CI 0.72 to 1.33; p = 0.9). Adverse events were minor in both studies. Conclusion: Aclidinium is effective and well tolerated in patients with moderate to severe COPD. Trial registration: ClinicalTrials.gov: NCT00363896 ACCLAIM/COPD I) and NCT00358436 (ACCLAIM/COPD II).
Note: Reproducció del document publicat a: http://dx.doi.org/10.1186/1465-9921-12-55
It is part of: Respiratory Research, 2011, vol. 12, p. 55
Related resource: http://dx.doi.org/10.1186/1465-9921-12-55
URI: http://hdl.handle.net/2445/34758
ISSN: 1465-9921
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
609861.pdf418.27 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons